Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$190.90 USD

190.90
7,972,058

+0.18 (0.09%)

Updated Oct 13, 2025 03:59 PM ET

After-Market: $190.70 -0.20 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 243)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings

by Zacks Equity Research

A number of healthcare companies are recording improvements in their financial numbers.

    Sheraz Mian headshot

    A Whole Lot of Nothing

    by Sheraz Mian

    Stocks haven't done much lately and the trend will likely continue for some time.

      Sheraz Mian headshot

      Is the Earnings Picture Improving?

      by Sheraz Mian

      There are some tell-tale signs of improvement in the aggregate earnings picture.

        Sheraz Mian headshot

        Is the Earnings Picture Improving?

        by Sheraz Mian

        There are some tell-tale signs of improvement in the aggregate earnings picture.

          Zacks Equity Research

          Stock Market News for July 20, 2016

          by Zacks Equity Research

          The Dow ended in the green for the eighth consecutive session on Tuesday following Johnson & Johnson's commendable quarterly performance

            Zacks Equity Research

            MedTech Industry Stock Outlook - July 2016

            by Zacks Equity Research

            Two full quarters of 2016 are behind us and, while we await second quarter results over the coming weeks, we hardly expect a change in trend in the bullish MedTech sector.

              Zacks Equity Research

              Stock Market News for June 03, 2016

              by Zacks Equity Research

              Benchmarks finished in the green on Thursday following encouraging U.S. private sector jobs data and gains in healthcare stocks

                Jeremy Mullin headshot

                Hedge Funds Are Buying These Stocks, Should You?

                by Jeremy Mullin

                Following the smart money can lead to big gains.

                  Kevin Cook headshot

                  Bear of the Day: AbbVie (ABBV)

                  by Kevin Cook

                  Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus

                    Tracey Ryniec headshot

                    3 Incredible Stocks Charts You Must See

                    by Tracey Ryniec

                    Beating the estimate 5 years in a row and shares at all time highs? No problem.

                      David Bartosiak headshot

                      5 Skyrocketing Momentum Stocks

                      by David Bartosiak

                      Five red hot momentum stocks breaking out to new highs

                        Kevin Matras headshot

                        Winning Stock Picks from the Top 5 Industries with the Biggest Job Growth

                        by Kevin Matras

                        Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include DG, UFPI, JNJ, TXRH and DEI.

                          Zacks Equity Research

                          MedTech Industry Stock Outlook - March 2015

                          by Zacks Equity Research

                          Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.

                            Zacks Equity Research

                            MedTech Industry Stock Outlook - March 2015

                            by Zacks Equity Research

                            Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.

                              Zacks Equity Research

                              MedTech Industry Stock Outlook - Dec. 2015

                              by Zacks Equity Research

                              While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                                Zacks Equity Research

                                MedTech Industry Stock Outlook - Dec. 2015

                                by Zacks Equity Research

                                While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                                  Sheraz Mian headshot

                                  Q3 Earnings Season Preview

                                  by Sheraz Mian

                                  All the big banks are on this week's reporting docket

                                    Brian Bolan headshot

                                    Crash-Proof Stocks To Buy Now

                                    by Brian Bolan

                                    Crashes happen, but not all stocks are treated the same during the crash.

                                      Zacks Equity Research

                                      MedTech Industry Stock Outlook - July/Aug 2015

                                      by Zacks Equity Research

                                      Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                                        Zacks Equity Research

                                        MedTech Industry Stock Outlook - July/Aug 2015

                                        by Zacks Equity Research

                                        Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                                          Sheraz Mian headshot

                                          Banks in Focus as Q2 Earnings Season Ramps Up

                                          by Sheraz Mian

                                          Banks had an overall decent time in Q2.

                                            Zacks Equity Research

                                            MedTech Industry Stock Outlook - March 2015

                                            by Zacks Equity Research

                                            The Republican- led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.

                                              Zacks Equity Research

                                              MedTech Industry Stock Outlook - March 2015

                                              by Zacks Equity Research

                                              The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.

                                                Zacks Equity Research

                                                MedTech Industry Stock Outlook - March 2015

                                                by Zacks Equity Research

                                                The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.

                                                  Zacks Equity Research

                                                  Vertex Pharmaceuticals Posts Narrower-than-Expected Loss

                                                  by Zacks Equity Research

                                                  Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.